Ovarian Cancer: Biomarker Proteomic Diagnosis in Progress
-
Published:2012-09-04
Issue:4
Volume:168
Page:910-916
-
ISSN:0273-2289
-
Container-title:Applied Biochemistry and Biotechnology
-
language:en
-
Short-container-title:Appl Biochem Biotechnol
Author:
Zhang Yong,Guo Bin,Bi Ran
Publisher
Springer Science and Business Media LLC
Subject
Molecular Biology,Applied Microbiology and Biotechnology,Biochemistry,General Medicine,Bioengineering,Biotechnology
Reference53 articles.
1. Andersen, M. R., Goff, B. A., Lowe, K. A., Scholler, N., Bergan, L., Drescher, C. W., Paley, P., & Urban, N. (2010). Use of a symptom index, CA125, and HE4 to predict ovarian cancer. Gynecologic Oncology, 116, 378–383. 2. Anderson, G. L. (2010). Ovarian cancer biomarker screening: still too early to tell. Women’s Health (London, England), 6, 487–490. 3. Anderson, G. L., McIntosh, M., Wu, L., Barnett, M., Goodman, G., Thorpe, J. D., Bergan, L., Thornquist, M. D., Scholler, N., Kim, N., O’Briant, K., Drescher, C., & Urban, N. (2010). Assessing lead time of selected ovarian cancer biomarkers: a nested case–control study. Journal of the National Cancer Institute, 102, 26–38. 4. Badgwell, D., Lu, Z., Cole, L., Fritsche, H., Atkinson, E. N., Somers, E., Allard, J., Moore, R. G., Lu, K. H., & Bast, R. C., Jr. (2007). Urinary mesothelin provides greater sensitivity for early stage ovarian cancer than serum mesothelin, urinary hCG free beta subunit and urinary hCG beta core fragment. Gynecologic Oncology, 106, 490–497. 5. Bast, R. C., Jr., Badgwell, D., Lu, Z., Marquez, R., Rosen, D., Liu, J., Baggerly, K. A., Atkinson, E. N., Skates, S., Zhang, Z., Lokshin, A., Menon, U., Jacobs, I., & Lu, K. (2005). New tumor markers: CA125 and beyond. International Journal of Gynecological Cancer, 15(Suppl 3), 274–281.
Cited by
12 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|